Rome Ther­a­peu­tics ad­vances dark genome drug af­ter com­plet­ing $72M Se­ries B ex­ten­sion backed by Big Phar­ma

Dark genome-fo­cused biotech Rome Ther­a­peu­tics has com­plet­ed an over­sub­scribed $72 mil­lion Se­ries B ex­ten­sion sup­port­ed by new Big Phar­ma back­ers, with an eye to ad­vanc­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER